跳至主要内容
临床试验/NL-OMON53651
NL-OMON53651撤回不适用

Improving Standard of Care lifestyle support for stage III NSCLC cancer patients - PERCUSSIO

MAASTRO clinic0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Pathological diagnosis of adequately staged (according to standard practice
  • using chest-CT, FDG-PET, brain imaging MRI/CT) NSCLC
  • Participant is willing and able to give informed consent for participation in
  • Aged 18 years or above
  • Scheduled to receive one of the following two therapeutic strategies:
  • o Concurrent chemotherapy and radiotherapy with photons (60 Gy in 30 fractions
  • of 2 Gy) followed by durvalumab in patients with stage III NSCLC
  • o Concurrent chemotherapy and radiotherapy with protons (60 Gy in 30 fractions
  • of 2 Gy) followed by durvalumab in patients with stage III NSCLC
  • Is able and willing to comply with all trial requirements

排除标准

  • - Mixed non-small cell lung cancer with other histology such as small cell lung
  • - Not able to comply with the study protocol
  • - Less than 18 years* old
  • - Pregnancy or not able to comply with adequate contraception in women with
  • child baring potential
  • - Previous radiotherapy to the chest for benign or malignant conditions,
  • including radiation for breast cancer
  • - Previous malignancies treated within 2 years before inclusion in the present
  • study, except for any in situ cancer or non-melanoma skin cancer when radically

研究者

相似试验